Lynn D. Morris

Johannesburg, GT, South Africa

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 187 publications

VRC01 exerted differential pressure on HIV-1 Env from subtypes B and C that continued in the first weeks post-diagnosis in the AMP trials.

VRC01 exerted differential pressure on HIV-1 Env from subtypes B and C that continued in the first weeks post-diagnosis in the AMP trials.

Journal: The Journal of infectious diseases

Published: March 17, 2026

Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.

Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.

Journal: Nature communications

Published: January 06, 2026

VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials.

VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibody.

Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibody.

Journal: medRxiv : the preprint server for health sciences

Published: September 29, 2025

Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.

Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.

Journal: bioRxiv : the preprint server for biology

Published: July 17, 2025

Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance.

Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance.

Journal: Journal of virology

Published: January 16, 2025

Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women.

Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women.

Journal: The Journal of antimicrobial chemotherapy

Published: January 10, 2025

Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines.

Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines.

Journal: Frontiers in immunology

Published: January 07, 2025

Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern.

Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern.

Journal: Scientific reports

Published: November 13, 2024

Novel polymorphic and copy number diversity in the antibody IGH locus of South African individuals.

Novel polymorphic and copy number diversity in the antibody IGH locus of South African individuals.

Journal: Immunogenetics

Published: May 31, 2024

Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.

Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.

Journal: PLOS global public health

Published: May 10, 2024

Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.

Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.

Journal: Nature communications

Published: March 23, 2024

Showing 1-12 of 187

Last Updated: 09/26/2026